Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings

By Jordan Chussler Published Feb 18, 11:52AM EST

Quick Read

Tempus AI (TEM) launched an AI algorithm identifying cancer patients responsive to platinum-based chemotherapy using RNA analysis.
Tempus reported preliminary Q4 revenue of $367M, up 83% year-over-year. Total contract value exceeded $1.1B.
Analysts set a consensus target of $85.69 for Tempus with nearly 50% upside.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.(Sponsor)

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings — © 24/7 Wall St.

Tempus AI, Inc. (NASDAQ:TEM) shares are climbing today after the company unveiled a new AI-powered cancer diagnostic algorithm, building momentum ahead of its Q4 2025 earnings report scheduled for February 24, 2026 after market close. The stock is trading at $57.29, up 6.86% over the past week.

What’s Driving the Move

Tempus announced its Pan-Cancer HRD-RNA algorithm today, an AI-driven tool that identifies Homologous Recombination Deficiency using RNA analysis rather than traditional DNA tests. This approach provides a real-time snapshot of tumor biology, helping doctors identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors. In real-world validation, patients with HRD-RNA positive metastatic pancreatic cancer showed significantly lower mortality risk compared to those receiving non-platinum therapies. The algorithm is currently available for research use, with clinical availability expected later in 2026.

Earnings Preview: What to Watch Tuesday

Tempus enters earnings week with strong momentum. The company already disclosed preliminary Q4 results in January, reporting revenue of $367 million, up 83% year-over-year, and total contract value exceeding $1.1 billion. Key items to watch in the full report include detailed financials, commentary on the path to profitability, and 2026 guidance.

What Analysts Say

Wall Street remains bullish despite recent volatility. The consensus analyst target sits at $85.69, representing nearly 50% upside from current levels. Analysts cite 2 Strong Buy and 5 Buy ratings, highlighting Tempus’s accelerating revenue growth and expanding AI-driven diagnostics platform.

The HRD-RNA launch signals continued innovation heading into earnings, but the stock remains down 18.54% over the past month. Tuesday’s report will provide more clarity on whether today’s momentum is supported by lasting fundamental strength or represents a short-term move ahead of results.

About the Author Jordan Chussler →

Jordan specializes in a wealth of finance topics, ranging from traditional equities, income investment vehicles and alternative assets to retirement savings, debt-based fixed-income securities and commodities, with a specific focus on gold and other precious metals. He takes pride in combining his personal interests and professional experience in finance and education to help readers increase their financial literacy and make better investment choices. Jordan has worked in digital publishing for 17 years after graduating from Lynn University as a member of both the Kappa Delta Pi International Honor Society and the U.S. Achievement Academy's All-American Scholar Program. He is the investing and banking editor for Money and previously served as managing editor of Weiss Ratings. As a contributing writer for BetterInvesting Magazine, Jordan covered topics focused on the fundamentals of investing, technical and fundamental analysis, mutual funds, debt securities, dividend investing, retirement savings strategies and passive income generation. His bylines can be seen at Nasdaq.com, Apple News, Money, MSN, BetterInvesting Magazine, Money Crashers, TipRanks, the Miami Herald and a dozen other newspapers.